Lornoxicam

Summary

Lornoxicam (CHEMBL1569487) is a phase-3 clinical-stage small-molecule non-steroidal anti-inflammatory drug (ATC M01AC05); indicated across 4 conditions including rheumatic disorder and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M01AC05
• Indications: 4 conditions
• Clinical trials: 25
• Chemistry: 371.8 Da · C13H10ClN3O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1569487
Name	Lornoxicam
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	54690031
ChEBI	CHEBI:31783
ATC	M01AC05
Molecular formula	C13H10ClN3O4S2
Molecular weight	371.8
InChIKey	WLHQHAUOOXYABV-UHFFFAOYSA-N

SMILES: CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3

IUPAC name: 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide

ChEBI definition: A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, antipyretic.

Also known as: CTX, Lorcam, Lornoxicam, NSC-759620, RO-139297, Xefo, SID49666507, LORNOXICAM, lornoxicam, SID174007229

Patent coverage: 4,195 distinct patent families (14,586 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,601 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Beta-lactamase, DNA polymerase beta, Prostaglandin G/H synthase 1, Bile salt export pump.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ABCB11	5.12	IC50	7560	nM	CHEMBL_ACT_18129098
P00811	5.1	Potency	7943	nM	CHEMBL_ACT_4695227

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
migraine disorder	2	MONDO:0005277	MONDO:0005277

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	7
PHASE4	5
Not specified	5
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00997750	PHASE4	COMPLETED	Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome
NCT01564680	PHASE4	COMPLETED	Lornoxicam vs. Paracetamol After Lower Abdominal Surgery
NCT01873807	PHASE4	UNKNOWN	HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL
NCT03038321	PHASE4	UNKNOWN	Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?
NCT03689465	PHASE4	UNKNOWN	PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
NCT02535221	PHASE3	RECRUITING	Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
NCT04296175	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
NCT01069055	PHASE3	UNKNOWN	Comparison of Lornoxicam and Paracetamol for Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair
NCT01134523	PHASE3	UNKNOWN	Regimens Comparison for Breast Cancers of Positive Lymph Nodes
NCT02750917	PHASE3	COMPLETED	Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty
NCT03006614	PHASE3	UNKNOWN	PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
NCT03949634	PHASE3	UNKNOWN	Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)
NCT00293631	PHASE2	COMPLETED	Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy
NCT00293657	PHASE2	COMPLETED	Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
NCT00568464	PHASE2	TERMINATED	Study on VCD/IE in the Patients With Ewing’s Sarcoma Family of Tumors (ESFT)
NCT01117948	PHASE2	TERMINATED	Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.
NCT01480752	PHASE2	COMPLETED	Reduction of Post-operative Endodontic Pain
NCT02043587	PHASE2	TERMINATED	Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
NCT03844763	PHASE1/PHASE2	UNKNOWN	Targeting the Tumor Microenvironment in R/M SCCHN
NCT05322330	PHASE2	UNKNOWN	Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin’s Lymphoma
NCT01055470	Not specified	COMPLETED	Comparative Clinical Trial of Lornoxicam to Diclofenac in Patients of Osteoarthritis of Knee Joint.
NCT02025166	Not specified	UNKNOWN	Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion
NCT02294344	Not specified	TERMINATED	The Clinical Efficacy of DFPP in Patients With AAGN
NCT02572596	Not specified	UNKNOWN	Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
NCT03780556	Not specified	COMPLETED	Lornoxicam With Low Dose Ketamine Versus Pethidine to Control Pain of Acute Renal Colic

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).